CME for Nurse Practitioners

Quick Take Vol. 89

Quick Take Vol. 88

Quick Take Vol. 87

Which antipsychotic should you choose for a woman with first-episode psychosis? When clozapine isn't an option for treatment-resistant schizophrenia, what actually works? Do real-world abuse data change how you select insomnia medications? Did serial ketamine outperform midazolam in a new inpatient trial? Can sustained anthocyanin intake improve cognition?

Quick Take Vol. 86

What are the teratogenic risks of zolpidem in pregnancy? Do SGLT2 inhibitors slow lithium-related kidney decline? Which antipsychotic works best for acute schizophrenia? Do herbals like Rhodiola or St. John's wort help in mild depression? When should antipsychotics be continued after substance-induced psychosis?

Quick Take Vol. 85

Does Cobenfy maintain its efficacy and safety after one year of use? Should we reconsider trazodone for depression-associated insomnia despite AASM guidelines? Is antidepressant monotherapy in bipolar I as risky as previously thought? Does inflammation explain treatment resistance in older depressed adults? What risk factors predict stimulant misuse and diversion in ADHD patients?

Quick Take Vol. 84

When should you taper a benzodiazepine, and how slowly? Does semaglutide reverse metabolic risk in schizophrenia patients on clozapine or olanzapine? Is EPA effective for TRD? Can brief psychotherapy enable safe antidepressant discontinuation? Is a ketogenic diet effective for depression and other psychiatric conditions?

Quick Take Vol. 83

When should you consider high-dose olanzapine instead of clozapine for treatment-resistant schizophrenia? How effective is aripiprazole augmentation versus switching strategies in older adults with depression? Can GLP-1 receptor agonists elevate lithium levels? Should inflammatory markers guide antidepressant selection? Is adjunctive propranolol effective for panic disorder?

Quick Take Vol. 82

What are the six key tips for switching oral antipsychotics? Does deprescribing antipsychotics after delirium improve outcomes in older adults? Why is xylazine overdose difficult to treat? What does the PAX-D study reveal about pramipexole for depression? Do bioequivalent medications always produce equivalent clinical results?

Quick Take Vol. 81

Can ondansetron improve negative symptoms in schizophrenia? Will lithium orotate prevent or reverse Alzheimer's disease?What predicts treatment response in bipolar disorder? Should we increase SSRI doses or try alternative strategies for inadequate response? Is trazodone safe for treating insomnia in alcohol use disorder?

Quick Take Vol. 80

How effective is the new antipsychotic KarXT using the number needed to treat metric? Can bright light therapy effectively treat bipolar depression without causing mania? Does IV haloperidol really increase cardiac risks as commonly believed? Can varenicline help reduce alcohol intake in people with alcohol use disorder? Does ashwagandha extract improve cognitive function in mild cognitive impairment?

Quick Take Vol. 79

How should clozapine monitoring change after FDA's REMS removal? Does cariprazine work equally well in older adults with bipolar disorder? Can semaglutide help treat alcohol use disorder? Why do older adults receive subtherapeutic antidepressant doses? Is saffron as effective as SSRIs for depression?

Quick Take Vol. 78

Can pramipexole help treatment-resistant bipolar depression? Does semaglutide work for clozapine-induced obesity? Which antipsychotics best prevent hospitalization after cannabis-induced psychosis? What treatments rank highest for treatment-resistant depression? How do gut microbiota differ in depression versus anxiety disorders?

Quick Take Vol. 77

What is the best antipsychotic for first-episode psychosis? Can lurasidone treat bipolar depression with severe anxiety? How much do SSRIs increase bleeding when combined with anticoagulants? Is adding salt to meals associated with depression and anxiety?

Quick Take Vol. 76

Can lumateperone effectively treat depression with mixed features? Can GLP-1 agonists manage antipsychotic-induced weight gain? Is quetiapine superior to lithium for treatment-resistant depression? Do antidepressants accelerate cognitive decline in dementia patients? How do probiotics and prebiotics affect depression, anxiety, and cognition?

Quick Take Vol. 75

What are the main considerations when choosing an antipsychotic for first-episode psychosis? How do side effects of antidepressants change over time? Do combinations of psychiatric medications increase Torsades risk? Is there sufficient evidence for psychedelics in treating substance use disorders? Can tea compounds benefit mood and sleep disorders through neurotransmitter modulation?

Quick Take Vol. 74

What are the main reasons disulfiram is underutilized for alcohol use disorder? How do different antipsychotics compare regarding QT prolongation risks? What is the optimal dosage of lurasidone for bipolar depression ? How does clozapine's effectiveness compare to other antipsychotics? Which non-benzodiazepine medication options show the best balance of efficacy and side effects for insomnia in psychiatric patients?

Quick Take Vol. 73

How do LAI antipsychotics impact mortality rates compared to oral medications in schizophrenia ? What dosages of medications are most effective for preventing bipolar disorder relapse and maintaining safety? Is olanzapine more effective than risperidone for managing BPS? Can lisdexamfetamine effectively treat methamphetamine use disorder? Does chronopharmacology impact psychiatric treatment efficacy and side effects?

Quick Take Vol. 72

Can GLP-1 receptor agonists effectively treat alcohol use disorder? Which antidepressants cause the most weight gain? Do antidepressants increase fall risk in older adults? How effective and safe is ketamine for bipolar depression? Is aripiprazole truly a lower metabolic risk antipsychotic compared to olanzapine?

Quick Take Vol. 71

What are the major risks of antipsychotic pneumonia and which medications increase this risk? How effective is metformin combined with lifestyle changes for managing antipsychotic-induced weight gain? What are the optimal lithium levels for maintenance treatment and acute mania? How does exercise potentially help improve depression symptoms through biological mechanisms? What role do B-complex vitamins play in cognitive function among depressed patients?

Quick Take Vol. 70

How does clozapine affect OCD behaviors in schizophrenia patients? What is the relationship between valproate dosage and weight gain? Which dopamine agonist works best for treatment-resistant depression? Does delirium increase dementia risk in elderly patients? What treatment approaches show the strongest evidence for stimulant use disorder?

Quick Take Vol. 69

How dangerous are clozapine-induced ileus and pneumonia compared to agranulocytosis? How does topiramate compare to naltrexone for alcohol use disorder? Should cariprazine be continued as maintenance therapy in bipolar disorder? How reliably can we diagnose Wernicke's encephalopathy? What role does gut bacteria play in major depression?

Quick Take Vol. 68

What are the main benefits of long-acting injectables for women with schizophrenia? How might vitamin D impact dementia risk? What effect does lithium have on bone mineral density? How common is alcohol withdrawal syndrome? What are the long-term outcomes for patients with psychotic disorders?

Quick Take Vol. 67

How common are antidepressant discontinuation symptoms and which medications are associated with higher rates? Can Akkermansia muciniphila help manage olanzapine-induced weight gain? How does climate change impact mental health outcomes? What is the current evidence for antidrug vaccines in treating substance use disorders? Are there cognitive deficits associated with COVID-19 infection and how significant are they?

Quick Take Vol. 66

Can donanemab slow Alzheimer's progression? Does clozapine's agranulocytosis risk persist beyond the initial treatment period? Can antipsychotics cause both catatonia and neuroleptic malignant syndrome? What is the suicide risk in Parkinson's disease patients? Can AI predict antidepressant response and remission in major depression?

Quick Take Vol. 65

Can SSRIs be safely combined with oral anticoagulants? Do long-term benzodiazepine users typically escalate doses over time? Are antidepressants effective for cognitive symptoms in late-life depression? How should psychosis, agitation and depression be managed in dementia patients? Which antidepressants perform best for efficacy, tolerability and outcomes in geriatric depression?

Quick Take Vol. 64

Commentaries on papers covering hypochondriasis mortality risk, antipsychotic withdrawal syndrome, stimulant use in pregnancy, the gut-brain connection in schizophrenia, and sedative use and fall risk in the elderly.

Quick Take Vol. 63

In this volume, we explore promising developments in psychiatric treatments, including a new drug (KarXT) for schizophrenia and an antipsychotic (iloperidone) for bipolar mania. This volume also investigates the use of machine learning to predict psychosis conversion, the differentiation between substance-induced psychosis and schizophrenia, and ways to reduce racial bias in physical restraint use in emergency rooms. Do we have an unconscious bias when making decisions about using restraints?

Quick Take Vol. 62

In this Quick Take volume, we discuss a recent trial that showed a doubled risk of relapse in patients with schizophrenia when antipsychotic medication was reduced. We also touch on the use of psilocybin for treatment-resistant depression, which sounds promising—still, the need for concurrent psychotherapy and the potential long-term safety risks must be considered. Additionally, we talk about using famotidine for COVID-19–induced brain fog, real-world evidence supporting long-acting injectable antipsychotics for bipolar disorder, and effective management of poststroke depression.

Quick Take Vol. 61

In this Quick Take volume, we revisit the utilization of droperidol as a strategy for handling agitation and ponder on the discontinuation of benzodiazepines and Z-drugs among hospitalized elderly patients. Are there alternate approaches for discontinuation that could be undertaken during hospitalization? We also question the efficacy of gabapentin in treating post-COVID-19 anosmia, its possible association with neurodegenerative diseases, and whether high-dose olanzapine is a feasible treatment for resistant schizophrenia. Finally, do antidepressants influence the effectiveness of psychotherapy?

Quick Take Vol. 60

In this Quick Take volume, our faculty discuss the effectiveness of adjunctive cariprazine in the treatment of major depressive disorder with inadequate response to antidepressants and low-dose risperidone for delirium in elderly orthopedic patients. Our experts also examine the efficacy of memantine for trichotillomania and skin-picking disorder and investigate the link between psychiatric disorders and increased risk for cardiovascular disease. Finally, the real-world effectiveness of pharmacologic treatments for bipolar disorder is discussed.

Quick Take Vol. 59

In this Quick Take volume, our expert faculty investigate the link between insomnia symptoms and stroke risk, analyze the long-term effectiveness of antipsychotics in treating schizophrenia, and examine the safety of oral antipsychotics for older adults after surgery. Our experts also assess the benefits and risks of medical cannabis in Parkinson's disease treatment and explore neuroradiological abnormalities in first-episode psychosis.

Quick Take Vol. 58

In this Quick Take volume, our expert faculty examine a range of critical topics, beginning with an exploration of plasma concentrations of SSRI/SNRI post-bariatric surgery and their impact on depressive symptoms. They also investigate the potential of psychedelics as transformative therapeutics in mental health care as well as the efficacy and safety of antidepressants in patients suffering from both depression and other medical diseases. Additionally, the use of daridorexant among patients with chronic insomnia and an international research agenda focusing on clozapine-resistant schizophrenia are discussed.

Quick Take Vol. 57

In this Quick Take volume, our expert faculty examine timely research on electroconvulsive therapy as an effective adjunct for clozapine in the treatment of ultra–treatment-resistant schizophrenia, trazodone as a possible first-line treatment for insomnia, and Silexan’s potential benefits for alleviating neuropsychiatric symptoms associated with post-COVID syndrome. Our faculty also discuss studies on medication risks, such as antipsychotic drugs and the risk for acute pancreatitis as well as benzodiazepines and the risk for suicide attempt.

Quick Take Vol. 56

In this Quick Take volume, our expert faculty examine research on the possible effects of prenatal exposure to antidepressants across various trimesters of gestation as well as the safety and efficacy of lithium augmentation for the management of treatment-resistant depression. Our faculty also discuss studies regarding antipsychotics and liver safety as well as inappropriate medication use among older adults.

Quick Take Vol. 55

In this Quick Take volume, our expert faculty examine research on tobacco use and nicotine dependence among adults with psychosis, the risk of irreversible sexual dysfunction associated with SSRIs, and the effects of dual orexin receptor antagonists on delirium prevention. Our faculty also discuss sleep disorders in Parkinson’s disease and the pharmacologic treatment of obsessive-compulsive disorder.

Quick Take Vol. 54

In this Quick Take volume, our expert faculty examine research on the association between NSAIDs and reduced rates of delirium, antidepressants and apathy, and victimization and violence among patients with schizophrenia. Our women’s health expert also discusses the efficacy and safety of zuranolone on patients with postpartum depression as well as the risks of major malformations in infants after maternal exposure to benzodiazepines.

Quick Take Vol. 53

In this Quick Take volume, our expert faculty examine research on the effects of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression; aripiprazole co-prescription on prolactin levels among hospitalized patients; and the use of colony-stimulating factor on the outcomes of patients undergoing clozapine rechallenge. Selected faculty experts also discuss the phenomenon of tardive syndromes and appropriate management for these as well as the effect of pharmacogenomic testing on the outcomes of major depressive disorder.

Quick Take Vol. 52

In his last Quick Take volume, Dr. James Phelps discusses selected papers on antidepressant use and withdrawal, focusing particularly on the shift from categorical to dimensional diagnostic approaches in mood disorders. He also reviews the latest CANMAT and ISBD guidelines on the management of bipolar depression and mixed states, the importance of nonmanic markers in assessing bipolar features, and implications for treatment options for bipolar depression.

Quick Take Vol. 51

In this Quick Take volume, Dr. James Phelps examines research on the use of atypical antipsychotics for various patient populations, such as patients with Parkinson’s disease psychosis, patients with poor response to clozapine, and young adults with psychotic and bipolar disorders. He also discusses systematic reviews on pharmacologic treatments for cocaine craving as well as the efficacy of dual orexin receptor antagonists for the treatment of insomnia.

Quick Take Vol. 50

In this Quick Take volume, Dr. James Phelps discusses research studies regarding haloperidol for the treatment of delirium in ICU patients, antidepressant use during pregnancy and the risk for gestational diabetes, and the risk for cardiovascular diseases associated with ADHD medications. He also tackles studies examining the associations between cannabis use and brain changes among youth as well as associations between oral contraceptives, antidepressants, and the risks for suicidal behavior and accidents among patients with premenstrual disorders.

Quick Take Vol. 49

In this Quick Take volume, Dr. James Phelps examines research studies on the effects of a smartphone-based self-management intervention for patients with bipolar disorder as well as pharmacogenetic testing on medication selection and remission among patients with major depressive disorder. He also discusses novel and emerging treatments for major depressive disorder, e-cigarette use patterns among patients attempting smoking cessation, and associations between antipsychotic use, substance use, and relapse risk in patients with schizophrenia.

Quick Take Vol. 48

In this Quick Take volume, Dr. James Phelps examines research studies on potential predictors for treatment response among various psychiatric conditions, such as baseline cognitive function for response trajectories in first-episode schizophrenia as well as C-reactive protein for SSRI response among patients with depression. He also discusses reviews on antidepressant discontinuation and the likelihood of relapse, mirtazapine as a potential augmentation strategy for clozapine-resistant schizophrenia, and the efficacy of lavender extract for the management of insomnia.

Quick Take Vol. 47

In this Quick Take volume, Dr. James Phelps examines research studies on medications with potential utility for various psychiatric conditions, such as N-acetylcysteine for schizophrenia, sublingual dexmedetomidine for acute agitation, and naltrexone–bupropion combination for binge-eating disorder. He also discusses reviews on the efficacy and safety of ketamine vs electroconvulsive therapy among patients with depression as well as knowledge gaps in the diagnosis and management of neuropsychiatric sequelae of COVID-19.

Quick Take Vol. 46

In this Quick Take volume, Dr. James Phelps discusses research studies on a novel automated intervention to extend ketamine efficacy as well as MDMA-assisted psychotherapy for posttraumatic stress disorder. He also examines studies on the possible associations between antidepressant use during pregnancy and neurodevelopmental disorders among children and SSRI dosing strategies for premenstrual syndromes. Finally, he presents recent findings on the risks for neurologic and psychiatric disorders associated with having had COVID-19 infection.

Quick Take Vol. 45

In this Quick Take volume, Dr. James Phelps examines research studies on lamotrigine and lithium combination for rapid cycling bipolar disorder, second-generation antipsychotics as adjunct treatments for major depressive disorder, and electroconvulsive therapy for the treatment of delirium. He also discusses research on microdosing with psilocybin mushrooms and the use of mood stabilizers for adjunct treatment of schizophrenia.

Quick Take Vol. 44

In this Quick Take volume, Dr. James Phelps discusses research studies that seek to shed light on the controversies regarding antidepressant efficacy, including papers on the estimates of the minimal clinically important difference (MCID), which antidepressants and omega-3 fatty acids have in relation to the treatment of depression. He also examines studies on the comparison between quetiapine and lithium for the treatment of bipolar depression as well as the effect of slower lamotrigine titration rates on the incidence of selected adverse events.

Quick Take Vol. 43

In this Quick Take volume, Dr. James Phelps examines research studies on psychotropic medications and adverse effects, such as the association between olanzapine concentration and metabolic dysfunction as well as antidepressants and the risk for fractures. He also examines research on the efficacy of pharmacologic and dietary supplement treatments for autism spectrum disorder, the efficacy of bright light therapy for perinatal depression, and a narrative review on the symptomatic vs disease-modifying effects of psychotropic drugs.

Quick Take Vol. 42

In this Quick Take volume, Dr. James Phelps examines research studies on clozapine, including the development of an international adult guideline for clozapine titration as well as the use of metformin for the prevention of clozapine-induced weight gain. He also discusses studies on anticholinergic medication misuse, optimal antipsychotic dosing for relapse prevention, and a widely read systematic umbrella review on the serotonin hypothesis.

Quick Take Vol. 41

In this Quick Take volume, Dr. James Phelps examines research studies on methylphenidate and other pharmacologic treatments for the treatment of apathy among patients with Alzheimer’s disease, folate and its derivatives for the treatment of various psychiatric disorders, and the efficacy of supraphysiologic doses of levothyroxine for adjunctive treatment of bipolar depression. He also discusses reviews on the efficacy of psychotherapies and pharmacotherapies for psychiatric disorders as well as the association between physical activity and the risk for depression.

Quick Take Vol. 40

In this Quick Take volume, Dr. James Phelps discusses research studies on the use of brexpiprazole for the treatment of borderline personality disorder as well as the use of psychotropic medications that act as functional inhibitors of acid sphingomyelinase (FIASMAs) for the prevention of serious medical outcomes among patients with COVID-19. He also examines systematic reviews on biomarkers of neuroprogression in bipolar disorder and the risks and benefits associated with the use of tranylcypromine in combination treatment. Finally, he presents recent guidelines on the management of psychosis in the context of mood disorders.

Quick Take Vol. 39

In this Quick Take volume, Dr. James Phelps examines research studies on factors affecting medication response among patients with posttraumatic stress disorder as well as interventions for reducing irritability among youth with ADHD. He also reviews meta-analyses on rapid tranquilization for patients with agitation and treatment strategies for patients with nonresponse to antidepressant therapy. Finally, he discusses the phenomenon of akathisia as an adverse effect of atypical antipsychotics.

Quick Take Vol. 38

In this Quick Take volume, Dr. James Phelps examines research studies on mirtazapine for the treatment of agitation among patients with Alzheimer’s disease, neurostimulation for the treatment of functional neurological disorder, and characteristics of patients who recommence clozapine therapy following treatment interruptions. He also discusses meta-analyses on the association between serotonin genetic variation and antidepressant response as well as the effects of caffeine on anxiety symptoms among patients with panic disorder.

Quick Take Vol. 37

Dr. James Phelps discusses research on mood disorders, including antidepressant-induced mood switching in bipolar disorder and recommended treatment strategies for sustained response in major depressive disorder. He also reviews research on adverse drug reactions associated with psychotropic medications and the possible roles of repetitive transcranial magnetic stimulation for smoking cessation and ketamine for relapse prevention for alcohol use disorder.

Quick Take Vol. 36

In this Quick Take volume, Dr. James Phelps discusses research studies on the use of the Young Mania Rating Scale in distinguishing youth with unipolar vs bipolar depression. He also tackles findings on the treatment of co-occurring sleep problems among children and adolescents with anxiety disorders and the efficacy of lithium in preventing suicide among veterans. Finally, he presents 2 studies on the use of SSRIs, particularly fluoxetine and fluvoxamine, for the prevention of serious medical outcomes among patients with COVID-19.

Quick Take Vol. 35

Dr. James Phelps discusses newly published research papers with practical implications, such as the use of clozapine for patients with COVID-19 infection and IV ketamine as treatment for treatment-resistant depression. Research on the concomitant use of antidepressants and benzodiazepines for patients with anxiety disorders, as well as the effect of zuranolone on postpartum depression, are also examined. Finally, Dr. Phelps discusses a new meta-analysis on the relationship between gut microbiota and psychiatric diagnoses.

Quick Take Vol. 34

Dr. James Phelps discusses research studies on treatment strategies for bipolar depression, such as atypical antipsychotics and intermittent theta burst transcranial magnetic stimulation, and how marketing bias can impact published data. He also presents more recent data on the effects of antipsychotic treatment on brain volume changes, as well as data on mood disorders as a risk factor for worse outcomes among patients with COVID-19. Finally, he shares results of a naturalistic study on the psychopharmacologic treatment of schizoaffective disorder.

Quick Take Vol. 33

Dr. James Phelps discusses relevant updates on the clinical presentation and management of psychiatric disorders. Research outcomes on antipsychotics and suicide risk reduction, vitamin D supplementation for the treatment of schizophrenia, and quetiapine for major depressive disorder with anxiety symptoms are examined. Dr. Phelps also re-examines newer research on the course of ADHD and interventions for the treatment of binge eating disorder (BED).

Quick Take Vol. 32

In this Quick Take volume, Dr. James Phelps presents recent research data, including efficacy and adverse outcomes, on commonly used psychopharmacologic agents. These include myocarditis from clozapine and suicidality among children and adolescents given SSRIs. Dr. Phelps also discusses research comparing stimulants and alpha-adrenergic agonists in the treatment of children with ADHD as well as predictors of diagnostic stability in patients with brief psychotic episodes.

Quick Take Vol. 31

Dr. James Phelps presents recent research data, including efficacy and adverse outcomes, on commonly used psychopharmacologic agents, such as venlafaxine, fluoxetine, and atypical antipsychotics, for the management of agitation in dementia and postmenopausal depression. He also reviews data on the phenomenon of polypharmacy in the treatment of bipolar disorder as well as psychiatric and neurologic outcomes associated with COVID-19 infection.

Quick Take Vol. 30

Dr. James Phelps discusses relevant updates on the clinical presentation and management of psychiatric disorders. Research outcomes on special populations, such as patients with postmenopausal depression, COVID-19, and agitation in dementia, are examined.

Quick Take Vol. 29

Dr. James Phelps discusses research on new interventions for psychiatric disorders, including marine omega-3 fatty acid supplementation for patients with borderline personality disorder and psilocybin for depression. He also reviews studies on methods for antipsychotic tapering to minimize relapse risk and frailty as a predictor of mortality for elderly patients with depression. Finally, he shares results of a study that compares recent clinical trials of psychotherapy in patients with posttraumatic stress disorder with concurrent substance use.

Quick Take Vol. 28

Dr. James Phelps discusses the use of ECT on various clinical populations, including adolescent patients and patients with comorbid depression and borderline personality features. He also reviews research on oxcarbazepine in the treatment of child and adolescent psychiatric symptoms and the role which the thyroid can play in psychiatric disorders. Finally, he shares findings from a systematic review on the risks and benefits of single vs multiple daily dosing regimens of psychotropics for patients with psychiatric disorders.

Quick Take Vol. 27

Dr. James Phelps discusses differential diagnoses and treatment strategies for drug-induced hyperthermic syndromes, including neuroleptic malignant syndrome and serotonin syndrome. He also reviews postmarketing safety concerns for esketamine as well as potential medications for Alzheimer's disease. Finally, he shares research on the neuropsychiatric symptoms associated with small vessel disease as well as suicide in patients with Parkinson's disease, including how our perceptions of this phenomenon can be impacted by medical paternalism.

Quick Take Vol. 26

Dr. James Phelps discusses research on COVID-19 and psychiatry, including the possible role of chlorpromazine as a potential antipsychotic of choice for COVID-19 patients and the association of psychiatric disorders with mortality among COVID-19 patients. He also reviews randomized controlled trials on the effects of psilocybin-assisted therapy on major depressive disorder and citalopram for bipolar depression. Finally, he shares new research on how the pretreatment brain connectome fingerprint may predict treatment response in depression.

Quick Take Vol. 25

Dr. James Phelps reviews research on the default mode network model of ADHD and its association with L-cystine, practical considerations on remote psychotherapy, and complementary and integrative therapies for geriatric mental health. In the second half of this 2-part Quick Take, he also discusses somatic treatments for child and adolescent depression, including antidepressants, psychotherapy, nutraceuticals, somatomotor techniques, and neuromodulatory tools.

Quick Take Vol. 24

Dr. James Phelps reviews research on the utility of electroconvulsive therapy for bipolar mania, on the impact of smoking on psychotropic blood levels, and on data examining psychological interventions as an alternative and add-on to antidepressant medication to prevent relapse. He also shares information on a paper exploring prazosin as a treatment option for alcohol withdrawal symptoms and a recent meta-analysis examining the presence of a dose-response relationship in SSRIs.

Quick Take Vol. 23

Dr. James Phelps discusses the latest updates on evidence-based prevention of Alzheimer's disease, procognitive effects of antidepressants for major depressive disorder, and therapy regimes for neuroleptic malignant syndrome. He also reviews the latest research regarding the risk of depressive relapse during pregnancy after discontinuation of antidepressants and rTMS treatment in pharmacoresistant obsessive-compulsive disorder.

Quick Take Vol. 22

Dr. James Phelps discusses an update of the pharmacologic options for treating borderline personality disorder and also a paper on the efficacy, safety, and tolerability of eszopiclone for PTSD and insomnia. Additionally, he shares research on the use of metformin and the risk of Alzheimer's Disease, which might delay the onset of Alzheimer's symptoms. Finally, he discusses the effects of long-acting injectable antipsychotics vs usual care in early-phase schizophrenia and the effectiveness of sequential psychological and medication therapies for insomnia disorder.

Quick Take Vol. 21

Dr. James Phelps discusses a meta-analysis of the metabolic consequences of 18 antipsychotics, a paper on the predictors of conversion from mild cognitive and behavioral impairments to dementia, and the risk of suicide with ADHD medications. He also shares research on the different cardiac abnormalities that can occur in anorexia nervosa. Finally, he discusses a commentary on the challenges in patients with alcohol and other substance use disorders during the COVID-19 pandemic, regarding treatment accessibility and the risks for developing substance use disorders.

Quick Take Vol. 20

Dr. James Phelps and Dr. Wegdan Rashad discuss antidepressant withdrawal. They review the benefit-risk ratio of antidepressants as well as the typical physical and emotional withdrawal symptoms. Finally, they discuss the need for greater recognition of withdrawal symptoms, patient education, and shared decision making.

Quick Take Vol. 19

Dr. James Phelps discusses several recent papers on COVID‑19 related to psychiatry. The research includes neurological symptoms and complications of COVID‑19; abuse, self-harm, and suicidal ideation during the pandemic; and the risks of clozapine treatment for COVID-19. He also reviews how COVID-19 increases the likelihood of prolonged grief disorder and the changes occurring in mental health services due to the pandemic.

Quick Take Vol. 18

Dr. James Phelps reviews research on the risks of oral contraceptives for certain women, the risks of stopping clozapine and the decision to restart it, and the efficacy and safety of lumateperone—a new antipsychotic for schizophrenia. He also explains the effect of lithium in preventing relapses in bipolar disorder. Finally, he discusses a network meta-analysis that compares the efficacy of psychotherapies, pharmacotherapies, and their combination for adult depression.

Quick Take Vol. 17

Dr. James Phelps reviews research on the use of esketamine combined with antidepressants for elderly patients with treatment-resistant depression, a paper on the possible efficacy of cannabinoids for the treatment of mental disorders, and the effectiveness of omega-3 and polyunsaturated fat for prevention of depression and anxiety. He also discusses a meta-analysis on the efficacy of long-acting injections in schizophrenia. Finally, he presents some interesting findings regarding the effects on the hypothalamic-pituitary axis with hormonal contraceptives.

Quick Take Vol. 16

Dr. James Phelps shares research on the role of antidepressants in the treatment of bipolar depression, current treatment options for adolescents with anorexia nervosa, and the role of memantine when used as an adjunct to escitalopram in older patients with depression. He also reviews 2 studies on the treatment of schizophrenia: One explores tDCS for negative symptoms, and the other rTMS for hallucinations.

Quick Take Vol. 15

Dr. James Phelps reviews the literature on lithium; 1 of the studies explores the use of low doses to prevent or delay the onset of dementia. The other study reviews the risks of lithium in pregnancy, including interesting new findings regarding cardiac risk. He also shares research on the medication approaches to dissociative disorders, the risk of benzodiazepines in pregnancy, and the effects of modafinil on cognitive function when used to treat depression.

Quick Take Vol. 14

Dr. James Phelps reviews research on the relationship between early eating behaviors and later development of eating disorders, on switching to imipramine vs adding mirtazapine to venlafaxine nonresponders, and on data examining a woman's subjective report of stress to her child's later development of a personality disorder. He also shares information on a paper exploring treatment options for depression in Parkinson's, psychotic symptoms in Lewy body dementia, and impulse-control problems in hypokinetic movement disorders. Finally, he delves into research that analyzes zolpidem with an SRI for the reduction of suicide ideation.

Quick Take Vol. 13

Dr. James Phelps reviews research on ketamine with mindfulness-based behavioral modifications for cocaine dependence, the possible relationship between antidepressants and hip fractures, and thyroid function screening in children and adolescents with mood and anxiety disorders. He also discusses a meta-analysis on the efficacy of 32 antipsychotics for the treatment of schizophrenia and how to better understand MRI in clinical psychiatry.

Quick Take Vol. 12

Dr. James Phelps discusses research on 2 papers that deal with dementia: One on using citalopram for agitation, and another that evaluates data suggesting antidepressants increase the risk of dementia. He also examines a proposed revision on a new model of mixed states, evidence-based choices for the treatment of irritability in autism spectrum disorder, and the regulatory contraindication that valproate carries for women of reproductive age.

Quick Take Vol. 11

Dr. James Phelps reviews research on medical conditions that co-occur with opioid abuse, treatment strategies for tardive dyskinesia, and the effect of psychoanalytic psychotherapy on reducing suicide attempts and self-harm. He also shares information on the connection between childhood trauma and schizotypal personality disorder and the efficacy of deep TMS for OCD.

Quick Take Vol. 10

Dr. James Phelps reviews research on the use of esketamine as adjunct to an antidepressant, a paper questioning the use of the bipolar I and II diagnoses, and for clinicians interested in substance abuse, research on cannabidiol for heroin use disorder. He also illustrates, with a paper on the best medication for delirium, why it is not adequate to only read the abstracts, as this may be misleading. Finally, he discusses a review on suicide after hospitalization, where patients with schizophrenia have the highest risk.

Quick Take Vol. 9

Dr. James Phelps reviews papers on the early diagnosis of OCD, recognizing the cardinal symptoms of dementia with Lewy bodies, and understanding cariprazine for bipolar depression. He also shares information on samidorphan as a medication for weight control in patients taking antipsychotics and the use of anti-inflammatory medication in depression.

Quick Take Vol. 8

Dr. James Phelps discusses research on topics like the number needed to harm applied to the risk of pneumonia associated with antipsychotics as well as 2 papers on benzodiazepines: 1 about the limited evidence base for medications to assist in benzodiazepine withdrawal and the other about the timing of physiologic dependence to benzodiazepines to guide their use. Also included are reviews on helping patients make well-informed choices among antidepressants, and re-examining the practice of antidepressant dose escalation when patients are not responding to standard doses.

Quick Take Vol. 7

Dr. James Phelps reviews the latest research on topics like pharmacogenomic testing in psychiatry and ketamine as well. Also covered is the literature on anticholinergic reduction in patients with dementia, childhood bipolar disorder, and augmentation with ondansetron in schizophrenia.

Quick Take Vol. 6

Dr. James Phelps shares research on antidepressant discontinuation, the art of deprescribing psychotropics, and a trial on lamotrigine for borderline personality disorder. He reviews the latest on augmentation strategies for treatment-resistant depression and covers a paper on how to use thyroid hormones in augmentation.

Quick Take Vol. 5

Dr. Phelps discusses diverse mood disorder-related topics starting with mixed states and moving to the use of the antipsychotic brexipiprazole in maintenance treatment of major depression. He also reviews a paper on new and quite unexpected antidepressants. Finally, Dr. Phelps describes a 2018 study on correlates between CRP and depression.

Quick Take Vol. 4

Dr. Phelps speaks in detail about clozapine, including first-line clozapine therapy, clozapine-induced neutropenia, and the use of clozapine for tardive dyskinesia. Furthermore, he summarizes a recent publication on the treatment of depression in schizophrenia and the different dementia treatments available.

Quick Take Vol. 1

Dr. James Phelps covers ketamine for suicidal ideation, antidepressants in schizophrenia with comorbid depression, and the teratogenicity of psychostimulants. He also reviews a large meta-analysis on whether any antidepressants are clearly better or worse than others as well as the use of liraglutide for weight loss in patients taking olanzapine or clozapine.

Quick Take Vol. 2

Dr. Phelps discusses the cardiovascular effects of stimulants in children and adolescents and the use of pimavenserin for Alzheimer's disease. Also, the CANMAT-ISBD guidelines for bipolar disorders, acute mania, and bipolar depression are summarized in this episode.

Quick Take Vol. 3

Dr. Phelps outlines the findings in recent publications about the use of lithium in pregnancy, the treatment of Alzheimer’s apathy, and utilizing MDMA in PTSD therapy. He covers a 2018 review on the pharmacotherapy of late-life depression and reviews a paper on "decisionally capable suicide" (i.e., patients who are neither depressed nor cognitively compromised but choose to end their life).